Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 7

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  BIOMARKER
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Personalized medicine from the perspective of oncologist

100%
Wysocki P. J., Handshuh P., Mackiewicz A.
Biotechnologia
|
2009
|
issue 5
18-26
EN
Personalized medicine is becoming very important in oncology. New achievements in genomics, molecular biology, toxicology or immunology lead to optimization and personalization of systemic therapy in cancer patients. Breast cancer is an excellent example for which personalized medicine is a real breakthrough in oncology. Targeted molecular therapies have significantly increased cancer patients' benefits and reduced adverse effects of the treatment. A large number of new promising anti-cancer agents and genomic tests are currently being tested in clinical trials. Results of the early clinical trails (Phase I and II) are very promising and provide a real hope for the fast progress of personalized oncology development.
2

Role of cysteine proteases and cystatins in periodontal disease pathogenesis and diagnosis

100%
Warwas M., Kaczmarek U., Golab K.
Postępy Higieny i Medycyny Doświadczalnej
|
2000
|
vol. 54
|
issue 6
879-894
EN
The paper presents a review of results concerning the role of host cysteine proteases, especially cathepsin B and cystatins in periodontal pathogenesis. Special attention was paid to the potential use of those biochemical parameters as biomarkers of periodontal disease activity.
3

Personalised medicine and its role in new drugs development

100%
Schmitt C., Stencel D.
Biotechnologia
|
2009
|
issue 5
84-87
EN
Personalized medicine is coming step by step to real clinical practice. The new era is forthcoming, in which 'one size does not fit all'. The hopes and expectations predominantly are based on achievements of molecular biology. Close connection between therapy and corresponding diagnostic test can lead to better defining patients target groups. Moreover, biomarkers defining is becoming a new approach to therapy stratification. Viral, oncologic, inflammatory and metabolic diseases are the examples of Roche involvement in this strategic way of development.
4

Guanine and inosine nucleotides, nucleosides and oxypurines in snail muscles as potential biomarkers of fluoride toxicity

100%
Rac M. E., Safranow K., Dolegowska B., Machoy Z.
|
2007
|
vol. 55
|
issue 3-4
153-160
EN
The aim of the present study was to determine the toxicity of fluorides on energy metabolism in muscles of the Helix aspersa maxima snail. Qualitative and quantitative analysis of purine compounds was performed in slices of foot from mature snails with high-performance liquid chromatography. Fluoride concentrations were measured using an ion-selective electrode and gas chromatography. The results show that exposure to fluoride pollution was accompanied by a statistically significant increase in fluoride concentrations in soft tissues. This effect was already noticeable with the smallest fluoride dose. Accumulation was greatest in the shell. There is a significant and positive correlation between fluoride concentrations in foot muscles and guanine and inosine nucleotides or uridine content. The content of low-energy guanylate, inosylate and oxypurine in foot muscles significantly increased with rising dose of fluoride. The difference as compared with controls was significant only for the highest dose of fluoride. Interestingly, uric acid, the final product of purine catabolism, dominated quantitatively in the foot muscles of snails. In conclusion, increased low-energy guanylate and inosylate as well as decreased xanthine concentrations in snail muscle can be indicators of the toxic influence of fluoride on the organism. The measuring of fluoride accumulation in the shell is the most suitable bioindicator of fluoride pollution in the environment.
5

Tumor markers studied with proteomic methods in blood and serum plasma

75%
Pietrowska M.
Biotechnologia
|
2009
|
issue 2
39-53
EN
Proteins are major components that directly determine phenotypes of cells and organisms, in either normal or pathological conditions. Because of numerous post-translational events that modify structure and function of proteins, the knowledge of genomes is only at the beginning of understanding of the full complexity of biological systems. 'Proteomics' is the study of proteomes, which addresses proteins' 3D structure, function, and their inter- and intracellular communication. Among primary goals of proteomics, there is discovery of biomarker for various human disease conditions. Plasma and serum are considered to be the source of choice in molecular diagnostics. The development of cancer involves transformation and proliferation of altered cell types that produce unique proteins and enzymes, which can significantly modify the pattern of serum peptides and proteins. The serum protein/peptide profiles that could be registered using different analytical methodologies appear to carry important information with direct clinical applicability. Importantly, such peptide profiles itself could become a new kind of potential tumor marker. These approaches are promising, but the results obtained are still preliminary. For example, detection of disease markers in the blood proteome could be hampered by its extremely low concentrations and the presence of a few abundant components (e.g., albumin and immunoglobulins), and thus development of more specific and sensitive analytical methods is still required. Nevertheless, identification of serum proteomic patterns or molecular signatures specific for different cancer types, stages and responses to therapy is possible at this moment. This article provides a comprehensive overview of current methodologies used for cancer biomarkers detection in blood proteome.
6

Biopharmaceuticals- a basic tool of modern pharmacotherapy

75%
Kaliszan R., Dlugokecka J.
Biotechnologia
|
2009
|
issue 5
33-49
EN
Current status of innovative drug industry is briefly presented with emphasis on new biopharmaceuticals introduced in the years 1995-2007. Adverse effects and problems of safety and effectiveness of these pharmacotherapeutics are reviewed. A separate part of the manuscript is devoted to the newly introduced methods of molecular diagnostics based on pharmacogenomics and employed in personalized medicine. Theranostic approach consisting in a joint use of drugs and companion diagnostics are characterized.
7

Evaluation of nephrotoxicity of cadmium in laboratory animals and humans

63%
Halatek T., Chmielnicka J.
|
|
vol. 47
|
issue 5
375-401
EN
available
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.